Greyledge Technologies is a clinical biotech company focused on autologous (from the patient) cell therapeutics including Platelet Rich Plasma (PRP).

Dr. David C. Karli recognized early on that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating therapeutic preparations wouldn’t meet the need for an evidence-based, precision medicine approach. As a result, he founded Greyledge. Dr. Karli remains responsible for all aspects of our company’s development, including the integratio...

Dr. David C. Karli recognized early on that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating therapeutic preparations wouldn’t meet the need for an evidence-based, precision medicine approach. As a result, he founded Greyledge. Dr. Karli remains responsible for all aspects of our company’s development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to Regenerative Medicine. His insight shapes our mission to this day: our emphasis remains focused on offering physicians and patients a custom cell therapy experience that produces results that reflect the uniqueness of every individual body.